



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 1 of 19	Attorney Docket Number	PC25132A	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
ESO		US- 5,082,838	01/21/1992	Naka, et al	
ESO		US- 5,817,819	10/06/1998	Furuya, et al	
ESO		US- 5,948,780	09/07/1999	Peterson Jr., et al	
ESO		US- 6,008,243	12/28/1999	Bender, et al	
ESO		US- 5,747,486	05/05/1998	Sohda, et al	
ESO		US- 5,403,843	04/04/1995	Akimoto, et al	
ESO		US- 5,284,661	02/08/1994	Morimoto, et al	
ESO		US- 5,521,181	05/28/1996	Meyer, et al	
ESO		US- 6,166,019	12/26/2000	Meyer, et al	
ESO		US- 5,334,596	08/02/1994	Hartman, et al	
ESO		US- 4,835,157	05/30/1989	Press, et al	
ESO		US- 5,792,767	08/11/1998	Meyer, et al	
ESO		US- 5,378,704	01/03/1995	Weller III	
ESO		US- 3,296,070	01/03/1967	Topliss, et al	
ESO		US- 2002-0156061	10/24/2002	Barvian, et al	
ESO		US- 2003-0004172	01/02/2003	Harter, et al	
ESO		US- 2002-019377	02/14/2002	Jenkins, et al	
ESO		US- 2002-0151558	10/17/2002	Andrianjara, et al	
ESO		US- 2002-0156069	10/24/2002	Picard, et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
ESO	•	WO 95/35296	12/28/1995	Takatani, et al		
ESO	•	WO 99/09485	02/24/2000	McClure, et al		
ESO	•	WO 02/34726	05/02/2001	Noe, et al		
ESO	•	WO 01/12611	02/22/2001	Blagg		
ESO	•	WO 02/34753	05/02/2002	Bronk, et al		
ESO	•	WO 01/05389	01/25/2001	Stallings, et a		

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
		Attorney Docket Number	PC25132A
Sheet 4	of 19		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	7 <sup>d</sup>
		Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>6</sup> (if known)				
ESO	1	WO 98/49899	11/12/1998	Atherall, et al		
ESO	1	WO 99/64400	12/16/1999	Salituro, et al		
ESO	1	WO 97/43239	11/20/1997	Van Zandt, et al		
ESO	1	WO 02/064080	08/22/2002	Andrianjara, et al		
ESO	1	WO 02/064572	08/22/2002	Andrianjara, et al		
ESO	1	WO 00/66584	11/09/2000	Gaudilliere, et al		

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Application Number	10/619,662
Filing Date	July 15, 2003
First Named Inventor	William Howard Roark
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	PC25132A

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	6	of	19
-------	---	----	----

**Complete if Known**

Application Number	10/619,662
Filing Date	July 15, 2003
First Named Inventor	William Howard Roark
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	PC25132A

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
ESO	<sup>6</sup>	EP 0935963	08/18/1999	McClure, et al		
ESO	<sup>6</sup>	EP 1138680	10/04/2001	Noe		
ESO	<sup>6</sup>	EP 0418797	03/27/1991	Baader, et al		
ESO	<sup>6</sup>	EP 0463592	01/02/1992	Baader, et al		
ESO	<sup>4</sup>	EP 0 915 093 A	05/12/1999	Okamura, et al		
ESO		EP 0 530 537 B1	01/08/1997	Akimoto, et al		

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	8	of	19
-------	---	----	----

**Complete if Known**

Application Number	10/619,662
Filing Date	July 15, 2003
First Named Inventor	William Howard Roark
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	PC25132A

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
ESO	•	EP 0 297 661 B1	09/16/1992	Janssens, et al		
ESO	•	EP 0 438 261 A2	07/24/1991	Akimoto, et al		
ESO	•	EP 0 297 661 A1	01/04/1989	Janssens, et al		
ESO	•	EP 0 282 133 B1	09/14/1988	Janssens, et al		
ESO	•	EP 260 057 A2	03/16/1988	Schmalzl, et al		
ESO	•	EP 0 463 592	01/02/1992	Baader, et al		

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <div style="text-align: center; font-weight: bold; font-size: 1.2em;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div style="text-align: center; font-style: italic; font-size: 0.8em;">(Use as many sheets as necessary)</div>		<div style="text-align: center; font-weight: bold; font-size: 1.1em;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/619,662</td> </tr> <tr> <td>Filing Date</td> <td>July 15, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>William Howard Roark</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> <tr> <td>Attorney Docket Number</td> <td>PC25132A</td> </tr> </table>		Application Number	10/619,662	Filing Date	July 15, 2003	First Named Inventor	William Howard Roark	Art Unit	1614	Examiner Name	Unknown	Attorney Docket Number	PC25132A
Application Number	10/619,662														
Filing Date	July 15, 2003														
First Named Inventor	William Howard Roark														
Art Unit	1614														
Examiner Name	Unknown														
Attorney Docket Number	PC25132A														

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
ESO		GB 2 097 396 A	11/03/1982	Seivaku, et al		
ESO		DE 41 37 437 A1	05/19/1993	Furrer, et al		
ESO		JP 5193260	03/08/1993			
ESO		DE 2441959	03/13/1975	Egli, et al.		
ESO		FR 4279M	08/16/1966	Vernin, et al		
ESO		JP 08 151380 A	06/11/1996			

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 12 of 19	Attorney Docket Number		PC25132A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Montana, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4); pp 353-261	
ESO		Clark, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinion in Drug Discovery & Development, 2000; 2(1); pp 16-25	
ESO		Chen, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654	
ESO		Derwent Abstract 96-068630/07, "New fused imidazole cpds. - possess inhibitory activity of adhesion molecule expression (Eng.)"	
ESO		Derwent Abstract 93-168431/21, "New Thiazolo-pyrimidine disone derivs. for treating arteriosclerosis"	
ESO		Derwent Abstract 91-001547/01, "New sulphur-Contg. fused pyrimidine cpds. - are endothelin and interleukin inhibitors for treatment and prevention of myocardial infarction, auto:immune diseases,etc."	
ESO		Derwent Abstract, 93271 E/44, "Cyclised pro-form of 5-fluoro-uracil derivs. - are orally administered antitumour agents without side effects of parent"	
ESO		Kaul, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: Isolation and Structures of the Major Sulfur-Free and Three Minor Sulfur-Containing Metabolites and Mechanism of Biotransformation", Journal of Pharmaceutical Sciences, Vol. 71, No. 8, August 1982; pp 897-900	
ESO		Kaul, et al, "Structure of a novel sulphur-containing metabolite of Acluracil (1-allyl-3,5-diethyl-6-chlorouracil)", Xenobiotica, 1982, Vol. 12, No. 8; pp 495-498	
ESO		Kaul, et al, "Identifizierung eines dritten S-haltigen Metaboliten von 1-Allyl-3,4-diethyl-6-chlorouracil und Bildungsmechanismus der SCH - Metaboliten", Arzneim.-Forsch./Drug Res., 1982; 32(I)(6); pp 610-612	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 13 of 19	Attorney Docket Number PC25132A		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite. No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Brown, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil Derivatives", J. Chem. Soc., 1972; pp 2385-2391	
ESO		Pecorari, et al, "Synthesis and Biological activity of Pyrimido [2,1-b] [1,3] Thiazine, [1,3]Thiazino[3,2-a]Purine and [1,2,3]Triazolo[4,5-d][1,3]Thiazino [3,2-a]Pyrimidine Derivatives and thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
ESO		De Melo, et al, "5-fluoro (3H) pyrimidine-4-ones; syntehse, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques francaises, 1992, 50, n1; pp 39-51	
ESO		Faskhutdinow, et al, Kim. Farm. Zh. 1988; 22(5); pp 557	
ESO		Tozkoparan, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331 (Weinheim, Germany): 1998; pp 201-206	
ESO		Chem. Abstr. 1992; 117; pp 143023e	
ESO		Chem. Abstr. 1988; 109; pp 162901r	
ESO		Boger, et al, "Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin. alpha. V. beta 3", Journal of the American Chemical Society 2001; 123: pp 1280-1288	
ESO		Silletti, et al, "Disruption of matrix metalloproteinase 2 binding to integrin alpha v beta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo", Proceeding of the National Academy of Sciences of the United States of America, 2001; 98(1); pp 119-124	
ESO		Milton, et al, "Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2", Bioorganic & Medicinal Chemistry Letters, Oxford, GB 1998; 8: pp 2623-2628	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 14	of 19	Attorney Docket Number	PC25132A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Hirota, et al, "Synthesis of 6-Substituted Thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones", J. Heterocycl. Chem., Vol 12, 1974; pp 717-721	
ESO		Rajappa, et al, "Synthesis of Thiophenes: Part III* - Further Variations in the Substitution Pattern", Indian J. Chem., Vol 12, 1974; pp 1-3	
ESO		HCAPLUS Abstract 1998: 542760; "Preparation of bicyclic-substituted hexahydrobenz [e] isoindoles as a1 adrenergic antagonists"	
ESO		HCAPLUS Abstract 1990: 514925; "Pyrimidines. 65. Synthesis of 6-substituted thieno [2,3-d] pyrimidine-2 4(1H,3H) - diones"	
ESO		Derwent Abstract 2000-687031/67, "New Xanthine derivatives are inhibitors of cellular processes mediated by interleukin-12 for treating inflammatory responses e.g. chronic inflammatory disease, chronic intestinal inflammation, arthritis, psoriasis and asthma (Eng)"	
ESO		Derwent Abstract 92-415690/50, "New Pyrimidinone derivs are angiotensin II antagonists for treating hypertension, congestive heart failure, renal failure, Alzheimer's disease, amnesia, schizophrenia, etc. (Eng)"	
ESO		Derwent Abstract 92-302020/37, "New fused pyrimidinone derivs. - are antitensin II antagonists to treat hypertension, congestive heart failure, Alzheimer's disease, amnesia, anxiety, schizophrenia, etc. (Eng)"	
ESO		Derwent Abstract 91-254180/35, "New angiotensin-II antagonising fused thiphenes derivatives - used for treating hypertension and circulatory diseases including heart diseases and stroke"	
ESO		Derwent Abstract 89-192246/26, "New 3-piperidinyl:alkyl-thieno: or furo pyrimidine-2,4-di:one cpds. - usefule as seratonin antagonists and alpha adrenergic blockers"	
ESO		Derwent Abstract 2000-195023/17, "New ipiperazinyl pyrimidine dione derivatives used as selective alpha-ID adrenoceptor antagonists for treating benign prostatic hyperplasia, hypertension, detrusor instability and incontinence (Eng)"	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
		Attorney Docket Number	PC25132A
Sheet	15	of	19

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Derwent Abstract 2001-158207/16, "New piperazinyl pyrimidine dione derivatives are selective alpha-1D adrenoceptor antagonists used for treatment of e.g. hypertension"	
ESO		Derwent Abstract 96-362624/36, "New Bi:cyclic substd. hexa:hydro-benz-isoindeole derivs. - are alpha-1 adrenergic antagonists, used in treatment of benign prostatic hyperplasia (Eng)"	
ESO		Derwent Abstract 89-008928/02, "New bi:cyclic heterocycle substd. hexa-hydro-1H-azepine-and pyrrolidine cpds., have anti-histaminic properties, for treatment of e.g. allergic rhinitis, allergic asthma, etc."	
ESO		Derwent Abstract 88-258874/37, "New 1-alkyl substd. benzimidazole derivs. - having anti-histaminic activity and used for treating allergic diseases such as allergic asthma"	
ESO		Derwent Abstract 91-216939/30, "New condensed heterocyclic glutemic acid dervis., - active against enzyme using folic acid and antitumour agents for treating e.g. leukemia"	
ESO		Derwent Abstract 99-080786/07, "New thiophene-and pyrrole-based hetero-aromatic compounds - are ant(agonists of cell surface receptors, useful e.g. for inhibiting unwanted cell growth e.g. due to cancer (Eng)"	
ESO		Derwent Abstract 97-165234/15, "New thieno-pyrimidine derivs. are endothelin antagonists - useful for treating e.g. acute renal failure, cardiac infarction, liver insufficiency, organ hypo-function and vasoconstriction (Eng)"	
ESO		Derwent Abstract 96-384384/38, "New 2,4(1H,3H)-di:oxo-5-aminoalkyl)thieno(2,3-d)-pyrimidine derivs. - are gonadotropin-releasing hormone antagonistic agents useful in prevention and treatment of sex hormone dependent diseases (Eng)"	
ESO		Derwent Abstract 95-382760/49, "Fused bicyclics as gonadotropin releasing hormone antagonists - used for treating hormone related cancers, benign prostatic hypertrophy, acne vulgaris, etc. (Eng)"	
ESO		Derwent Abstract 93-299636/38, "New condensed heterocyclic oligo-glutamate derivs. - used as water soluble antitumour agent and have bood storage stability in cells"	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 16	of 19	Attorney Docket Number PC25132A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Derwent Abstract 93-078155/10, "New antitumour condensed pyrimidine derivs. - for treating chorlocarcinoma, leukemia, breast adenocarcinoma, squamous cells carcinoma, lung cancer, lympho sarcoma, etc. and also rheumatism (Eng)"	
ESO		Derwent Abstract 92-218561/27, "Antitumoural condensed heterocyclic oligo:glutamate derivs. - for treating leukemia, squamous cell carcinoma, lymphatic sarcoma, small cell cancer of the lung etc. (Eng)"	
ESO		Derwent Abstract 96-267825/27, "New hexa:hydro benz(e)isoindole cpds. - are useful in treatment of benign prostatic hyperplasia (Eng)"	
ESO		Derwent Abstract 94-248420/30, "Furano- and thieno- (3,2-c)piperidone carboxamido-acids - are fibrinogen receptor antagonists, inhibit blood platelet aggregation, used in thrombi and emboli treatment"	
ESO		Derwent Abstract 91-075241/11, "Heterocyclic peptide derivs. useful as renin inhibitors - in the treatment of hypertension, congestive heart failure, retro-viral diseases and central nervous system disorders"	
ESO		HCAPLUS Abstract 1996:580284: "Preparation of heterocyclyl-substituted benz[3]isoindoles as x1 adrenergic antagonists"	
ESO		Liverton, et al, "Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinones and quinazolinones as potent fibrinogen receptor antagonists", Bioorganic & Medicinal Chemistry Letters, 1998; 8(5); pp 483-486	
ESO		Ogawa, et al, "Studies on positive inotropic agents V", Chem Pharm Bull, 1988; 36(6); pp 2253-2258	
ESO		Chemical Abstract CHEMCATS: AN 2001: 142935 for Order no. A1240/0056923 "Screening Collection", Zelinsky Institute of Organic Chemistry, Russia, 2000	
ESO		Chemical Abstract CHEMCATS: AN 2001:2519212, 2001:2519208, and 2001:2519206 for Order no.s CHS 1938401, CHS 1938397, and CHS 1938395, respectively, "Chemstar Product List", Chemstar Ltd. Russia, 2001	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 17 of 19	Attorney Docket Number	PC25132A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Chemical Abstract: CHEMCATS: AN 2001:2624610, 2001:2320591, 2002:928648, 2002:925092, 2002:926648, and 2002:927094 for Order nos. STOCKIN-22756, A1336/0060317, STOCKIS-85693, STOCKIS-77305, STOCKIS-81043, and STOCKIS-82046, respectively, "Ambinter:Exploratory Library", Ambinter, Paris, 2002	
ESO		Chemical Abstract CHEMCATS: AN 2001:1621701, 2001:1621700, 2001:1433023, 2001:1433022, and 2001:1433020 for Order nos. Z-007159, Z-007158, C-055659, C-055658, and C-055656, respectively, "Scientific Exchange Product List", Scientific Exchange, Inc., USA, 2001	
ESO		Chemical Abstract: Abstract No. 54:2375e for Nesterov, et al, Compound: Pyrimido '5,4-d pyrimidine-2, 4(1H, 3H)-dione, 6-(benzylthio)-, RN 00382-60-3, USA 1960	
ESO		Chemical Abstract CAPLUS: Abstract No. 128:243870 (1998:224550) for Murata, et al, "Regioselective synthesis of 6-substituted lumazines by using highly reactive lumazine 6-triflate", Germany 1997; 17-22	
ESO		Chemical Abstract CAPLUS: Abstract No. 128:243871 (1989:224554) for Kim, et al, "Side chain reactions of 6-acetyl-1,3,7-trimethylumazine", Germany 1997; 41-44	
ESO		Chemical Abstract CAPLUS: Abstract No. 126:212115 (1997:100238) for Abou-Hadeed, et al, "Pteridines CVIII Reactions of 6,7-dichloro-1,2-dimethylumazine with sulfur nucleophiles", Pteridines 1996; 7(4); 113-122	
ESO		Chemical Abstract CAPLUS: Abstract No. 107:58977 (1987:458977) for Sladowska, et al, "Synthesis and properties of amides of 1-benzyl-3-methyl-an 1-butyl-3-phenyl-7-methyl-4-oxo-2-thioxo (2,4-dioxo)-1,2,3,4-tetrahydropyrido '2,3-dipyrimidine-6-carboxylic acids", Farmaco, Ed.Sci. 1986; 41(12); 954-963	
ESO		Chemical Abstract CAPLUS: Abstract No. 87:152121 (1977:552121) for Lespagnol, et al, "Study on antifolic agest. 1. Derivatives of 4-nitrobenzene-1,3-dicarboxylic acid", Bull. Soc. Pharm. Lille 1977; 33(1); 67-77	
ESO		Chemical Abstract CAPLUS: Abstract No. 101:16805 (1984: 416805) for Ghose, et al, "A general distance-geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors", J. Med. Chem. 1984; 27(7); 901-914	
ESO		Reiter, et al, "Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket", Bioorganic & Medicinal Chemistry Letters, 1999; 9; 127-132	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 18 of 19	Attorney Docket Number	PC25132A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Derwent Abstract 95-051281/07, "New benzo- and pyrido- 1,2,4-thiadiazine dioxides - are angiotension II inhibitors, use in treatment of hypertension and congestive heart failure"	
ESO		Chemical Abstracts, Vol 125, No. 13, 1996, Abstract No. 167964d; XP002198554	
ESO		Database Crossfire Bulletin, Online, Database accession no. 786662; XP002198556	
ESO		Shkurko, et al, Khim. Geterotsikl. Soedin, 1977; 6; pp 821-824	
ESO		Database Crossfire Bulletin, 'Online, Database accession no. 7297869; XP002198557	
ESO		Yamamoto, et al, "Direct Introduction of ACYL and Ethoxycarbonyl, Groups Into Pyrimidine Through the Trimethyl-Stannyl Derivatives" Heterocycles, 1995; 41(6); pp 1275-1290	
ESO		Database Crossfire Bulletin, 'Online, Database accession no. 139954; XP002198558	
ESO		Hunt, et al., "Pyrimidines. Part X. Pyrimidine, 4:6-Dimethylpyrimidine, and their 1-Oxides," J. Chem. Soc., 1959; pp 525-530	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/619,662
		Filing Date	July 15, 2003
		First Named Inventor	William Howard Roark
		Art Unit	1614
		Examiner Name	Unknown
Sheet 19 of 19	Attorney Docket Number	PC25132A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO		Database Crossfire Bulletin, 'Online, Database accession no. 791572; XP002198559	
ESO		Sakasi, et al, "Studies in Pyrimidine Derivatives. XVII. Synthesis of Pyrimidine-4-Carboxyl Heterocycles", 1979; 13; pp 235-236	
ESO		Chemical Abstracts, Vol. 79, No. 11, Abstract No. 66394; XP002198555	
ESO		Chemical Abstracts CA Online! CASREACT AN 105:226286 of Vinsova, J. et al, "Antituberculotics XXXVII. Preparation of the functional derivatives of 6-methyl-2-pyridinecarboxylic acid substituted in position 4 and its 1-oxides" CESK. FARM. 1985;34(10:430-436 (XP002202692)	
ESO		Hanauske-Abel HM. et al, "Pyrroloquinoline quinone and molecules mimicking its functional domains. Modulators of connective tissue formation?" Federation of European Biochemical Studies Letters 1987, 214(2); 236-243 (XP002202687)	
ESO		Rateb, et al, "Synthesis of heterocyclic compds. from delta-unsaturated 1,3-diketo-esters Part III. ethyl 3-cyano-6-styryl-2-pyridone-4-carboxylates and their degradation products", Journal of the Chemical Society 1960, 1430-1434 (XP002202688)	
ESO		Chemical Abstracts: AN 61:6987c "Preparation of pyridinedicarboxaldehydes" (XP002202689)	
ESO		Chemical Abstracts: AN 64:6607g "Compounds with potential antitubercular activity" (XP002202690)	
ESO		Chemical Abstracts: AN 55:10440b "Solubilizing agents. V. Pyridinecarboxamides" (XP002202691)	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.